Coherus Aiming For More Than 10% Slice Of US Adalimumab Market

US-Based Firm Has December 2021 FDA Goal Date

Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.

Growth Strategy on Mechanism of Golden Metallic Gears. Growth Strategy on the Mechanism of Golden Cogwheels with Lens Flare. Growth Strategy - Illustration with Glowing Light Effect.
Coherus believes its customer-focused approach will stand it in good stead for the multi-billion-dollar adalimumab market • Source: Shutterstock

Coherus BioSciences, Inc. aims to capture greater than 10% of the adalimumab market upon expected biosimilar entry in 2023, buoyed by its product, “patient-focused offering and manufacturing scale,” which it is confident “will match what payers are looking for.”

Earlier this month, the US-based player revealed a US Food and Drug Administration goal for its CHS-1420 adalimumab biosimilar candidate...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.